Icon PLC (ICLR) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a ...

Investors might want to bet on Icon PLC (ICLR), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to ...

On this news, ICON’s stock price fell $59.03, or 21%, to close at $221.73 per share on October 24, 2024, thereby injuring investors. What Is The Lawsuit About?

NEW YORK CITY, NY/ ACCESS Newswire/ April 2, 2025/ Bleichmar Fonti& Auld LLP announces that it has filed a class action lawsuit for violations of the federal securities laws against ICON plc and ...

"ICON’s strong results in this report reflect the dedication, expertise, and innovation that drive our teams globally," said Steve Cutler, CEO. "Our consistent leadership in phase 1 clinical ...

ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit Provided by PR Newswire Mar 13, 2025, 8:05:00 PM ...

Icon Plc (NASDAQ: ICLR) is a contract research organization (“CRO”). In the Q3 2024 letter, I highlighted our investment in Medpace (MEDP) another CRO that directly competes with Icon.

It was also announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022. The presentation will be webcast live from 2.00pm ET.

Deadline Soon: ICON plc (ICLR) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit Provided by Business Wire Apr 9, 2025, 9:00:00 AM ...